Coagulation inhibitors in the treatment of sepsis

Keyphrases

• Anti-inflammatory Drugs 20%
• Anticoagulants 20%
• Antithrombin III (ATIII) 40%
• Clinical Testing 20%
• Clotting Cascade 20%
• Clotting System 20%
• Coagulation Inhibitors 100%
• Critically Ill Patients 20%
• High Dose 20%
• Lack of Efficacy 20%
• Low Mortality 20%
• Mortality Risk 20%
• Patient Benefit 20%
• Phase II Study 60%
• Physiological Derangement 40%
• Potential Toxicity 20%
• Recombinant Human Activated Protein C 80%
• Sepsis 100%
• Sepsis Model 20%
• Sepsis Shock 20%
• Sepsis Treatment 100%
• Septic Shock 20%
• Supportive Care 20%
• Survival Benefit 20%
• Therapeutic Role 20%
• Therapeutic Strategies 20%
• Tissue Factor Pathway inhibitor-2 (TFPI-2) 40%

Medicine and Dentistry

• Anticoagulant 12%
• Antiinflammatory Agent 12%
• Antithrombin III 25%
• Blood Clotting 12%
• Blood Clotting Inhibitor 100%
• Drotrecogin Alfa 50%
• Drug Megadose 12%
• Sepsis 100%
• Septic Shock 12%
• Supportive Care 12%
• Tissue Factor Pathway Inhibitor 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 12%
• Antiinflammatory Agent 12%
• Antithrombin III 25%
• Blood Clotting Inhibitor 100%
• Drotrecogin 62%
• Sepsis 100%
• Septic Shock 12%
• Tissue Factor Pathway Inhibitor 25%